Regeneration mechanism discovered in mice could provide target for drugs to combat chronic liver disease

Credit: CC0 Public Domain

A newly-discovered molecular mechanism that allows damaged adult liver cells to regenerate could pave the way for drugs to treat conditions such as cirrhosis or other chronic liver diseases where regeneration is impaired.

The mechanism, identified in mice, was made by researchers at the University of Cambridge's Gurdon Institute.

It has long been known that the human liver is one of the organs that can regenerate its own tissue after short-term injury. But chronic damage in conditions such as alcohol abuse, and certain viral infections, leads to impaired regeneration and cirrhosis (scarring), with eventual loss of liver function.

The by which adult liver trigger the regenerative response, and how this fails in , remain largely unknown. Around 30 million people across Europe suffer from chronic liver diseases, for which there is currently no cure, with liver transplants being the only treatment for liver failure. Scientists are therefore exploring how to trigger the intrinsic regenerative capacity of the liver, as an alternative means to restore function.

Researchers used mice and liver organoids ('mini-livers' generated in the lab from mouse liver cells) to study adult liver regeneration. They discovered that a molecule called TET1 is produced in healthy adult liver cells during the first steps of regeneration, and that this process is mimicked in liver organoids, where it has a role in stimulating organoid growth. The work is described in a paper published in the journal Nature Cell Biology.

Dr. Luigi Aloia, first author of the paper and postdoctoral researcher at the Gurdon Institute, said: "We now understand how adult liver cells respond to the changes caused by tissue injury. This paves the way for exciting future work to boost cell regeneration in chronic liver disease, or in other organs where regeneration is minimal such as the brain or pancreas."

TET1 and similar molecules are known to be essential in the developing embryo, where cells divide and differentiate to produce all the different organs of the body. But this study is the first to demonstrate that the activity of TET1 underpins regeneration in adult mouse liver tissue.

The adult liver is formed by two main types of cells: hepatocytes, which perform many of the liver's functions, and ductal cells, which form the network of tiny ducts delivering bile to the intestine. After acute (short-term) damage hepatocytes are able to regenerate, but after more severe injury they are not. After severe or chronic injury, the ductal cells become capable of generating both new hepatocytes and new ductal cells to replenish the liver tissue, through induction of an identity-switching process known as plasticity.

The researchers, in collaboration with colleagues in the UK and Germany, explored the molecular mechanism that provides ductal cells with this power to regenerate the tissue. They showed that TET1 activates a chemical switch—known as an epigenetic modification—on the ductal cell's DNA. This switch allows genes to 'turn on' so that the cell can respond to changes in the environment such as damage, and activate the program when needed.

Dr. Meritxell Huch, who led the research, said: "Our finding pinpoints TET1 as the protein that enables plasticity of the ductal cells and their regenerative capacity in response to injury. Because the epigenetic switch activated by TET1 does not modify the genetic sequence of the cell, but the mechanism by which the genes are expressed, it represents a target that could be modified by drugs."

Explore further

Researchers identify functions of key genes responsible for liver regeneration

More information: Epigenetic remodelling licences adult cholangiocytes for organoid formation and liver regeneration, Nature Cell Biology (2019). DOI: 10.1038/s41556-019-0402-6 ,
Journal information: Nature Cell Biology

Citation: Regeneration mechanism discovered in mice could provide target for drugs to combat chronic liver disease (2019, November 4) retrieved 28 October 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors